Tag Directory / HEALTHCARE     showing 1–20 of 290



New EPA rule could loosen limits on medical device sterilization gas emissions / Medical Express

medicalxpress - The U.S. Environmental Protection Agency (EPA) is proposing to loosen limits on emissions of ethylene oxide, a gas used to sterilize many medical devices that is also linked to cancer.

#healthcare #publichealth #governmentpolicy #medicaldevices #oncology #hospitaloperations #cancerresearch #supplychain


Monday, March 16, 2026, 10:22 pm / permalink 20846 / 3 stories in 0 min


Officials examine deaths after plasma donations in Winnipeg / Medical Express

medicalxpress - Canadian health officials are investigating the deaths of two people who donated plasma at private clinics in Winnipeg, Manitoba.

#healthcare #publichealth #governmentpolicy #hospitaloperations


Monday, March 16, 2026, 9:23 pm / permalink 20845 / 3 stories in 58 min


Healthcare tech inovation: Lessons from HIMSS 2026 / Healthcare Dive

healthcaredive - At HIMSS 2026, AWS took the stage with Jupiter Medical Center and Rady Children's Health. Read the key lessons from last week's Views from the Top Session.

#healthcare #digitalhealth #hospitaloperations #healthcarefinance #cybersecurity


Monday, March 16, 2026, 4:21 am / permalink 20798 / 14 stories in 18 hrs


Neoadjuvant GOLP Prolongs EFS Among Patients with Resectable High-Risk Intrahepatic Cholangiocarcinoma / ESMO

esmo - Findings from the ZSAB-neoGOLP study

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch #clinicaltrials


Monday, March 16, 2026, 3:21 am / permalink 20797 / 3 stories in 19 hrs


Trial finds vitamin D supplements don't reduce COVID severity but could reduce long COVID risk / Medical Express

medicalxpress - In a large, randomized trial, researchers at Mass General Brigham found that high-dose vitamin D3 did not reduce COVID-19 infection severity, but may impact long COVID outcomes. Results of the study are published in The Journal of Nutrition.

#healthcare #publichealth #infectiousdisease #longcovid #clinicaltrials #nutrition #vitamind #supplements


Monday, March 16, 2026, 1:22 am / permalink 20790 / 2 stories in 21 hrs


NRG-LU005 Trial: Atezolizumab Plus Chemoradiotherapy in Limited-Stage Small Cell Lung Cancer / OncoDaily

oncodaily - A major international clinical trial, NRG-LU005, has provided important new insight into how immunotherapy should be used in limited-stage small cell lung cancer (SCLC). While immune checkpoint inhibitors have significantly […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Monday, March 16, 2026, 12:23 am / permalink 20789 / 4 stories in 21 hrs


FDA Drug Approval Marks a First for a Disease — But It’s Not Autism / MedCity

Frank Vinluan / medcitynews - Leucovorin is now approved for cerebral folate deficiency months after FDA Commissioner Marty Makary claimed the decades-old generic drug had promise for treating autism. The FDA’s review was based on published literature and real-world evidence.The post …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #drugdevelopment #fda #autism


Sunday, March 15, 2026, 12:22 pm / permalink 20779 / 4 stories in 33 hrs


A new triple negative breast cancer target: Why HORMAD1 could guide treatment choices / Medical Express

medicalxpress - A gene that is typically active only in reproductive cells may hold the key to new treatments for triple negative breast cancer, according to new research published in the journal Nature Communications. Scientists from the Breast Cancer Now Toby Robins Re…

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 11:21 pm / permalink 20776 / 4 stories in 47 hrs


Alfasigma Pays $300M for Rights to GSK Rare Liver Disease Drug On Track for FDA Decision / MedCity

Frank Vinluan / medcitynews - GSK licensed to Alfasigma global rights to linerixibat, a drug developed to treat the rare liver disease primary biliary cholangitis (PBC). The move follows Alfasigma’s 2025 voluntary market withdrawal of Ocaliva, a PBC drug that had sparked safety concer…

#healthcare #pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment #healthcarefinance


Saturday, March 14, 2026, 8:21 pm / permalink 20771 / 2 stories in 2 days


Roche’s big hope breast cancer drug fails in crucial first-line trial / Endpoints

Elizabeth Cairns / endpoints - Roche’s breast cancer pill, which the company recently said had the potential to become its biggest-ever selling drug, has failed in what is arguably its most important Phase 3 trial. The persevERA ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 7:21 pm / permalink 20770 / 5 stories in 2 days


‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up / MedCity

Marissa Plescia / medcitynews - Novo Nordisk dropped its lawsuit against Hims & Hers and launched a new collaboration. The deal is advantageous for both companies, experts say.The post ‘They Need Each Other’: Why Hims & Hers and Novo Nordisk Made Up appeared first on MedCity News.

#obesity #healthcare #pharmaceuticals #novonordisk #weightloss #digitalhealth #healthcarefinance #supplychain


Saturday, March 14, 2026, 2:22 pm / permalink 20763 / 3 stories in 2 days


Fitch upgrades UCHealth’s rating to ‘AA+’ / Beckers

Andrew Cass / beckershospitalreview - Aurora, Colo.-based UCHealth’s credit rating was upgraded to “AA+” from “AA” by Fitch. The upgrade reflects the health system’s very strong financial profile, benefiting from its market position in a growing service area and a long track record of robust …

#healthcare #publichealth #governmentpolicy #digitalhealth #medicaldevices #oncology #hospitaloperations #cancerresearch


Saturday, March 14, 2026, 2:22 pm / permalink 20762 / 5 stories in 2 days


Antonio Calles: RECITE Trial Findings on Romiplostim for Chemotherapy-Induced Thrombocytopenia / OncoDaily

oncodaily - Antonio Calles, Medical Oncologist at Hospital General Universitario Gregorio Marañón and faculty member of the Lung and Other Thoracic Tumours faculty group of the ESMO, shared a post by NEJM, […]

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #cancerresearch


Saturday, March 14, 2026, 12:23 pm / permalink 20760 / 2 stories in 2 days


The appendix evolved at least 32 times across 361 species, so it's 'unlikely to be a useless evolutionary accident,' research finds / LiveScience

livescience - Two researchers explore the evolutionary history of the appendix and its role in human health.

#healthcare #wildlife #animalhealth


Saturday, March 14, 2026, 11:22 am / permalink 20758 / 2 stories in 2 days


Personalized Support Program Improves Smoking Cessation for Cervical Cancer Survivors – UCLA Health / OncoDaily

oncodaily - UCLA study shows program doubles quit rates for women and offers a cost-effective approach A new study led by UCLA researchers suggests that a personalized counseling program can significantly help […]

#healthcare #publichealth #oncology #behavioralhealth #cancerresearch


Saturday, March 14, 2026, 6:21 am / permalink 20747 / 2 stories in 2 days


Grail names new CEO as Bob Ragusa retires / Endpoints

Jared Whitlock / endpoints - Grail on Thursday announced that its CEO, Bob Ragusa, will retire and is handing the reins to its current president Josh Ofman. The cancer screening company said the move was the culmination of long-term succession ...

#healthcare #biotech #medicaldevices #oncology #healthcarefinance #cancerresearch


Saturday, March 14, 2026, 4:21 am / permalink 20744 / 5 stories in 2 days


Measles outbreaks could fuel rise in fatal complication, physicians warn / Beckers

Mackenzie Bean / beckershospitalreview - As measles continues spreading across the U.S. at a pace not seen in decades, physicians are warning about a rare but often fatal neurological complication that can emerge years after initial infection, KFF Health News reported March 13. Subacute sclerosi…

#healthcare #publichealth #governmentpolicy #cdc #vaccinesafety #infectiousdisease


Saturday, March 14, 2026, 2:21 am / permalink 20742 / 8 stories in 2 days


Vanderbilt Health president, CEO to retire / Beckers

Paige Twenter / beckershospitalreview - Jeff Balser, MD, PhD, president and CEO of Vanderbilt Health and dean of Vanderbilt University’s school of medicine, plans to retire from both roles Dec. 31, according to a March 12 news release from the Nashville, Tenn.-based organizations. During his 17…

#healthcare #hospitaloperations #healthcarefinance #researchfunding


Saturday, March 14, 2026, 2:21 am / permalink 20741 / 2 stories in 2 days


AMA: Physicians' use of AI doubled from 2023 to 2026 / Fierce

fiercehealthcare - A survey fielded earlier this year found 81% of doctors use AI in a professional context, with an average of 2.3 use cases per physician. Respondents were largely bullish on the technology's ability to boost clinical care and work efficiency, but still ha…

#healthcare #publichealth #governmentpolicy #digitalhealth #hospitaloperations #cybersecurity


Saturday, March 14, 2026, 1:21 am / permalink 20740 / 14 stories in 2 days


Ipsen pulls cancer drug Tazverik from market over safety risks / Endpoints

Nicole DeFeudis / endpoints - Ipsen is pulling its cancer drug Tazverik from the market after an independent data monitoring committee found safety concerns in a confirmatory trial. The committee reported cases of secondary cancers that begin in blood-forming tissue ...

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda #productrecall #oncology #cancerresearch


Saturday, March 14, 2026, 12:23 am / permalink 20738 / 3 stories in 2 days


Back to Top


HEALTHCARE Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...


FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...



NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.